Cargando…

Reassessing the Reassessment of suPAR in Glomerular Disease

Detalles Bibliográficos
Autores principales:	Meijers, Björn K. I., Reiser, Jochen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294199/ https://www.ncbi.nlm.nih.gov/pubmed/25593929 http://dx.doi.org/10.3389/fmed.2014.00059

Ejemplares similares

suPAR, a Circulating Kidney Disease Factor
por: Wei, Changli, et al.
Publicado: (2021)

suPAR: An Inflammatory Mediator for Kidneys
por: Sudhini, Yashwanth Reddy, et al.
Publicado: (2022)

suPAR and Team Nephrology
por: Trachtman, Howard
Publicado: (2014)

Urinary CD80 and Serum suPAR as Biomarkers of Glomerular Disease among Adults in Brazil
por: Zen, Renata de Cássia, et al.
Publicado: (2023)

suPAR: The Molecular Crystal Ball
por: Thunø, Maria, et al.
Publicado: (2009)

Assay-related differences in SuPAR levels: implications for measurement and data interpretation
por: Vasbinder, Alexi, et al.
Publicado: (2022)

suPAR as a prognostic biomarker in sepsis
por: Donadello, Katia, et al.
Publicado: (2012)

suPAR to Risk-Stratify Patients With Malaria
por: Stefanova, Veselina, et al.
Publicado: (2022)

SuPAR mediates viral response proteinuria by rapidly changing podocyte function
por: Wei, Changli, et al.
Publicado: (2023)

Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study
por: Hayek, Salim S., et al.
Publicado: (2017)

Reassessing the Safety of Pill-in-the-Pocket Propafenone
por: Kim, Andrew G, et al.
Publicado: (2023)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis Patients
por: Torino, Claudia, et al.
Publicado: (2018)

A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease
por: Spinale, Joann M., et al.
Publicado: (2014)

The Association of uPA, uPAR, and suPAR System with Inflammation and Joint Damage in Rheumatoid Arthritis: suPAR as a Biomarker in the Light of a Personalized Medicine Perspective
por: Benucci, Maurizio, et al.
Publicado: (2022)

Fetal Renal Echogenicity Associated with Maternal Focal Segmental Glomerulosclerosis: The Effect of Transplacental Transmission of Permeability Factor suPAR
por: Shuster, Shirley, et al.
Publicado: (2018)

Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab
por: Alachkar, Nada, et al.
Publicado: (2018)

SuPAR - A future prognostic biomarker in emergency medicine
por: Østervig, Rebecca M, et al.
Publicado: (2015)

Reassessment of Pioglitazone for Alzheimer’s Disease
por: Saunders, Ann M., et al.
Publicado: (2021)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Independently Predicts Severity and Length of Hospitalisation in Patients With COVID-19
por: Enocsson, Helena, et al.
Publicado: (2021)

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
por: Rovina, Nikoletta, et al.
Publicado: (2020)

suPAR remains uninfluenced by surgery in septic patients with bloodstream infection
por: Rabensteiner, Jasmin, et al.
Publicado: (2016)

Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis
por: Garnæs, Emilie, et al.
Publicado: (2019)

suPAR Surprises as a Biomarker of Invasive Outcomes in Pleural Infection
por: Idell, Steven, et al.
Publicado: (2020)

The Perspective of Vitamin D on suPAR-Related AKI in COVID-19
por: Liao, Tzu-Hsien, et al.
Publicado: (2022)

The Association of suPAR with Cardiovascular Risk Factors in Young and Healthy Adults
por: Wohlwend, Niklas Fabio, et al.
Publicado: (2023)

Sex Differences in Circulating Soluble Urokinase‐Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease
por: Mehta, Anurag, et al.
Publicado: (2020)

Detection of Inflammatory Biomarker suPAR in COVID-19 Disease With CHORUS TRIO Instrument
por: Helena, Cerutti, et al.
Publicado: (2023)

Assessing and Reassessing the Association of Comorbidities and Coinfections in COVID-19 Patients
por: Khan, Aryaan, et al.
Publicado: (2023)

suPAR links a dysregulated immune response to tissue inflammation and sepsis-induced acute kidney injury
por: Nusshag, Christian, et al.
Publicado: (2023)

Detection of suPAR in the Saliva of Healthy Young Adults: Comparison with Plasma Levels
por: Gustafsson, Anna, et al.
Publicado: (2011)

SuPAR predicts postoperative complications and mortality in patients with asymptomatic aortic stenosis
por: Hodges, Gethin W, et al.
Publicado: (2018)

Plasma levels of the active form of suPAR are associated with COVID-19 severity
por: Huang, Mingxiang, et al.
Publicado: (2020)

suPAR Cut-Offs for Risk Stratification in Patients With Symptoms of COVID-19
por: Altintas, Izzet, et al.
Publicado: (2021)

Predictive value of suPAR in AKI: a systematic review and meta-analysis
por: Huang, Yan, et al.
Publicado: (2022)

Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update
por: Velissaris, Dimitrios, et al.
Publicado: (2022)

Reassessing Revascularization Strategies in Coronary Artery Disease and Type 2 Diabetes Mellitus
por: Liang, Bo, et al.
Publicado: (2021)

Innate immune response-mediated late increase in SuPAR in multi-trauma patients
por: Timmermans, K, et al.
Publicado: (2013)

Reassessing blood acetylcholinesterase in dementia
por: Han, Pengcheng
Publicado: (2015)

Reassessing carrier status for dystrophinopathies
por: Newcomb, Tara M., et al.
Publicado: (2016)

Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical Patients
por: Iversen, Esben, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h306d29cedhshk4anilh80eldu